亨丁顿舞蹈症是一种以常染色体显性遗传为特征的神经退行性疾病,其临床表现主要表现为运动障碍、认知功能障碍以及精神障碍。早期科学家们对亨丁顿舞蹈症的致病机制进行了深入研究,目前,国内针对该病的治疗方法主要分为两大类。一类是...亨丁顿舞蹈症是一种以常染色体显性遗传为特征的神经退行性疾病,其临床表现主要表现为运动障碍、认知功能障碍以及精神障碍。早期科学家们对亨丁顿舞蹈症的致病机制进行了深入研究,目前,国内针对该病的治疗方法主要分为两大类。一类是技术治疗,涵盖了神经细胞异种移植技术、超声技术联合微泡技术和中枢神经原位再生技术等。另一类是药物治疗,包括表没食子儿茶素没食子酸酯、Deutetrabenazin药物、二甲双胍和GPR52受体反向激动剂等。尽管这些治疗方法目前仍处于早期实验阶段,尚未广泛应用于临床治疗,但它们为亨丁顿舞蹈症患者的康复带来了希望。本文旨在综述近年来国内在亨丁顿舞蹈症治疗方法研究方面取得的进展。Huntington’s disease is a neurodegenerative disease characterized by autosomal dominant inheritance. Its clinical manifestations are mainly manifested as movement disorders, cognitive dysfunction and mental disorders. Early scientists conducted in-depth research on the pathogenic mechanism of Huntington’s disease. At present, domestic treatment methods for the disease are mainly divided into two categories. The first category is technical treatment, which covers nerve cell xenograft technology, ultrasound technology combined with microbubble technology, and central nerve in situ regeneration technology. The other category is drug therapy, including epigallocatechin gallate, Deutetrabenazin drugs, metformin and GPR52 receptor inverse agonists. Although these treatments are still in the early experimental stages and have not yet been widely used in clinical treatment, they offer hope for the recovery of Huntington’s chorea patients. This article aims to review the progress made in the research on treatment methods for Huntington’s disease in recent years.展开更多
文摘亨丁顿舞蹈症是一种以常染色体显性遗传为特征的神经退行性疾病,其临床表现主要表现为运动障碍、认知功能障碍以及精神障碍。早期科学家们对亨丁顿舞蹈症的致病机制进行了深入研究,目前,国内针对该病的治疗方法主要分为两大类。一类是技术治疗,涵盖了神经细胞异种移植技术、超声技术联合微泡技术和中枢神经原位再生技术等。另一类是药物治疗,包括表没食子儿茶素没食子酸酯、Deutetrabenazin药物、二甲双胍和GPR52受体反向激动剂等。尽管这些治疗方法目前仍处于早期实验阶段,尚未广泛应用于临床治疗,但它们为亨丁顿舞蹈症患者的康复带来了希望。本文旨在综述近年来国内在亨丁顿舞蹈症治疗方法研究方面取得的进展。Huntington’s disease is a neurodegenerative disease characterized by autosomal dominant inheritance. Its clinical manifestations are mainly manifested as movement disorders, cognitive dysfunction and mental disorders. Early scientists conducted in-depth research on the pathogenic mechanism of Huntington’s disease. At present, domestic treatment methods for the disease are mainly divided into two categories. The first category is technical treatment, which covers nerve cell xenograft technology, ultrasound technology combined with microbubble technology, and central nerve in situ regeneration technology. The other category is drug therapy, including epigallocatechin gallate, Deutetrabenazin drugs, metformin and GPR52 receptor inverse agonists. Although these treatments are still in the early experimental stages and have not yet been widely used in clinical treatment, they offer hope for the recovery of Huntington’s chorea patients. This article aims to review the progress made in the research on treatment methods for Huntington’s disease in recent years.
